Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine is a potential treatment option for patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 gliomas.
Authors
- Yasuyuki Kakurai (ORCID: https://orcid.org/0000-0002-4086-1716)
- Yonehiro Kanemura (ORCID: https://orcid.org/0000-0002-1894-1824)
- Daisuke Kuga (ORCID: https://orcid.org/0000-0002-9493-0748)
- Akitake Mukasa (ORCID: https://orcid.org/0000-0001-7776-9086)
- Ryuta Saito (ORCID: https://orcid.org/0000-0002-2484-1360)
- Shunichi Koriyama (ORCID: https://orcid.org/0000-0001-6613-8131)
- Kazuya Motomura (ORCID: https://orcid.org/0000-0002-4376-1104)
- Yoshiki Arakawa (ORCID: https://orcid.org/0000-0003-4626-4645)
- Masayuki Kanamori (ORCID: https://orcid.org/0000-0002-3380-1192)
- Kazuhiko Mishima
- Fumiyuki Yamasaki (ORCID: https://orcid.org/0000-0003-0164-6295)
- Kazuhiko Sugiyama
- Motoo Nagane (ORCID: https://orcid.org/0000-0002-0018-1652)
- Yoshitaka Narita (ORCID: https://orcid.org/0000-0003-4303-6006)
- Toshihiro Kumabe (ORCID: https://orcid.org/0000-0002-1507-6214)
- Koji Isobe
- Hideo Nakamura (ORCID: https://orcid.org/0000-0003-2944-234X)
Institutions
- Kurume University (JP)
- Kyushu University (JP)
- Daiichi Sankyo (Germany) (DE)
- Kyorin University (JP)
- Tohoku University (JP)
- Kyoto University (JP)
- National Cancer Center (US)
- Research Institute for Innovation and Technology (BR)
- Osaka National Hospital (JP)
- Daiichi-Sankyo (Japan) (JP)
- Hiroshima University Hospital (JP)
- Daiichi Sankyo (India) (IN)
- Saitama International Medical Center (JP)
- Tokyo Women's Medical University (JP)
- National Cancer Center Hospital East (JP)
- Nagoya University (JP)
- Kitasato University (JP)
- Saitama Medical University (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1093/neuonc/noaf258
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Daiichi-Sankyo
- Daiichi Sankyo Europe